文献速递毛发、甲与色素性疾病

两项随机临床试验中巴瑞替尼治疗成人重度斑秃的综合安全性分析

Integrated safety analysis of baricitinib in adults with severe alopecia areata from two randomized clinical trials.
PubMed 文献 · Br J Dermatol · 2023-01-01

该分析汇总BRAVE-AA1和BRAVE-AA2两项试验中1303例接受巴瑞替尼治疗的重度斑秃患者的安全性数据,共1868患者年暴露。安慰剂对照期痤疮频率巴瑞替尼高于安慰剂,4mg组CPK升高高于安慰剂和2mg组。全巴瑞替尼组严重感染发生率低,未报告死亡,整体安全性特征与巴瑞替尼已知安全性一致。

要点

  • 安慰剂对照期痤疮频率巴瑞替尼高于安慰剂。
  • CPK升高在巴瑞替尼4mg组高于安慰剂和2mg组。
  • 全巴瑞替尼组严重感染发生率低,未报告死亡。

核心结论

  • 该重度斑秃综合安全性分析与巴瑞替尼整体安全性特征一致,与特应性皮炎相比观察到一些差异,可能归因于斑秃的疾病特征。

研究设计与样本

  • 汇总两项试验(适应性II/III期BRAVE-AA1和III期BRAVE-AA2,NCT03570749和NCT03899259)的患者水平安全性数据。
  • 数据分三个数据集:安慰剂对照数据集(至第36周)、扩展数据集(至数据截止,持续治疗患者)和全巴瑞替尼数据集(至数据截止,所有接受任何剂量巴瑞替尼的患者)。

主要发现

  • 共1303例患者接受巴瑞替尼,反映1868患者年暴露(中位532天)。
  • 安慰剂对照期(基于巴瑞替尼4mg组)最常报告的治疗中出现的不良事件为上呼吸道感染、鼻咽炎、头痛、痤疮和血肌酸磷酸激酶(CPK)升高。
  • 安慰剂对照期痤疮频率巴瑞替尼高于安慰剂,CPK升高巴瑞替尼4mg组高于安慰剂和巴瑞替尼2mg组。
  • 全巴瑞替尼组严重感染发生率低(n=16,发生率0.8),机会性感染1例(发生率0.1),带状疱疹34例(发生率1.8)。
  • 全巴瑞替尼组主要不良心血管事件(心肌梗死)经判定1例(发生率0.1),肺栓塞1例(发生率0.1),非黑色素瘤皮肤癌以外的恶性肿瘤3例(发生率0.2),胃肠道穿孔1例(发生率0.1),未报告死亡。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Baricitinib, an oral, selective, reversible Janus kinase (JAK)1/JAK2 inhibitor, is an approved treatment for adults with severe alopecia areata (AA) in the USA, European Union and Japan. OBJECTIVES: To report safety data for baricitinib in patients with severe AA from two clinical trials including long-term extension periods. METHODS: This analysis includes pooled patient-level safety data from two trials, an adaptive phase II/III trial (BRAVE-AA1) and a phase III trial (BRAVE-AA2) (ClinicalTrials.gov, NCT03570749 and NCT03899259). Data are reported in three datasets: (i) the placebo-controlled dataset (up to week 36): baricitinib 2 mg and 4 mg vs. placebo; (ii) the extended dataset (up to the data cutoff): patients remaining on continuous treatment with baricitinib 2 mg or 4 mg from baseline; and (iii) the all-baricitinib dataset (all-BARI, up to the data cutoff): all patients receiving any dose of baricitinib at any time during the trials. Safety outcomes include treatment-emergent adverse events (TEAEs), adverse events of special interest and abnormal laboratory changes. Proportions of patients with events and incidence rates (IR) were calculated. RESULTS: Data were collected for 1303 patients who were given baricitinib, reflecting 1868 patient-years of exposure (median 532 days). The most frequently reported TEAEs during the placebo-controlled period (based on the baricitinib 4-mg group) were upper respiratory tract infection, nasopharyngitis, headache, acne and elevated blood creatine phosphokinase (CPK). During the placebo-controlled period, the frequency of acne was higher with baricitinib than placebo, and elevated CPK was higher with baricitinib 4 mg than placebo and baricitinib 2 mg. In all-BARI, the IR of serious infections was low (n = 16, IR 0.8). There was one opportunistic infection (IR 0.1), and 34 cases of herpes zoster (IR 1.8). There was one positively adjudicated major adverse cardiovascular event (myocardial infarction) (IR 0.1), one pulmonary embolism (IR 0.1), three malignancies other than nonmelanoma skin cancer (IR 0.2) and one gastrointestinal perforation (IR 0.1). No deaths were reported. CONCLUSIONS: This integrated safety analysis in patients with severe AA is consistent with the overall safety profile of baricitinib. Some differences with atopic dermatitis were noted that may be attributable to the disease characteristics of AA.

来源:Br J Dermatol,查看原文。版权归原作者所有。

引用

  1. King B, Mostaghimi A, Shimomura Y, et al. Integrated safety analysis of baricitinib in adults with severe alopecia areata from two randomized clinical trials. Br J Dermatol. 2023. PMID: 36763878. doi:10.1093/bjd/ljac059

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。